Abstract:Over the past decade, topically applied drug products have experienced extraordinary price increases, due to the shortage of multisource generic drug products. This occurrence is mainly related to the underlying challenges evolved in topical bioequivalence documentation. Although there has been continuing regulatory efforts to present surrogate in vitro methods to clinical endpoint studies, there is still a continued need for cost- and time-efficient alternatives that account for product specificities. Hence, this work intended to expose bioequivalence assessment issues for complex topical formulations, and more specifically those related with product efficacy guidance. As a model drug and product, a bifonazole 10 mg/g cream formulation was selected and two different batches of the commercially available Reference Product (RP) were used: RP1 that displayed lower viscosity and RP4 which presented high, but not the highest, viscosity. In vitro human skin permeation testing (IVPT) was carried out and the results were evaluated by means of the traditional bioequivalence assessment approach proposed by the EMA, as well as by the Scaled Average Bioequivalence assessment approach proposed by the FDA. Based on previous experience, there was an expectation of a high level of variability in the results, thus alternative methods to evaluate local drug skin availability were developed. More specifically, an infected skin disease model, where ex vivo human skin was infected and ATP levels were used as a biological marker for monitoring antifungal activity after product application. The results showed that permeation equivalence could not be supported between the different RP batches. In contrast, this statistical difference between the formulation batches was not indicated in the disease model. Nevertheless, in pivotal IVPT studies, the lowest permeant formulation (RP4) evidenced a higher antifungal in vitro activity as reported by the lower levels of ATP. A critical appraisal of the results is likewise presented, focusing on an outlook of the real applicability of the regulatory guidances on this subject.

In vitro permeation testing for the evaluation of drug delivery to the skin

Revisiting techniques to evaluate drug permeation through skin

Relating transdermal delivery plasma pharmacokinetics with in vitro permeation test (IVPT) findings using diffusion and compartment-in-series models

Towards the understanding of the IVPT results variability-Development, verification and validation of the PBPK model of caffeine in vitro human skin permeation

Developing a method for the study of perfusion effects in topical product pharmacokinetics

Method to determine the impact of substantivity on ex vivo skin-permeation

In vitro and in silico computational methods for assessing vaginal permeability

Unravelling Microarray Patch Performance: The Role of In Vitro Release Medium and Biorelevant Testing

Design and development of topical liposomal formulations in a regulatory perspective

Methods for evaluating penetration of drug into the skin: A review

Validation of an In vitro-in vivo Assay System for Evaluation of Transdermal Delivery of Caffeine

Alternatives to Biological Skin in Permeation Studies: Current Trends and Possibilities

In vitro studies into establishing therapeutic bioequivalence of complex topical products: Weight of evidence

Comparative Analyses of Bioequivalence Assessment Methods for In Vitro Permeation Test Data

Optical Methods for Non-Invasive Determination of Skin Penetration: Current Trends, Advances, Possibilities, Prospects, and Translation into In Vivo Human Studies

Assessment of skin permeability to topically applied drugs by skin impedance and admittance

Evaluation of Formulation Parameters on Permeation of Ibuprofen from Topical Formulations Using Strat-M® Membrane

Effect of Receptor Solution in Studies of In Vitro Permeation Test (IVPT)

Influence of in Vitro Methods, Receptor Fluids on Percutaneous Absorption and Validation of a Novel in Vitro Method.

Use of an In Vitro Skin Parallel Artificial Membrane Assay (Skin-PAMPA) as a Screening Tool to Compare Transdermal Permeability of Model Compound 4-Phenylethyl-Resorcinol Dissolved in Different Solvents

In vitro evaluation of the percutaneous absorption of progesterone in anhydrous permeation-enhancing base using the Franz skin finite dose model and mass spectrometry